Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hunan Nucien Pharmaceutical Co (SHSE:688189) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hunan Nucien Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥1,259.4 Mil.
Hunan Nucien Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-127.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Nucien Pharmaceutical Co EV-to-EBIT Related Terms
Hunan Nucien Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Nucien Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Nucien Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hunan Nucien Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hunan Nucien Pharmaceutical Co's EV-to-EBIT falls into.
Hunan Nucien Pharmaceutical Co's current Enterprise Value is ¥1,462.0 Mil.
Hunan Nucien Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-127.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Nucien Pharmaceutical Co (SHSE:688189) has a EV-to-EBIT of -11.46 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hunan Nucien Pharmaceutical Co and its competitors. According to the industry distribution chart, Hunan Nucien Pharmaceutical Co ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Hunan Nucien Pharmaceutical Co's EV-to-EBIT too high?
Hunan Nucien Pharmaceutical Co's current EV-to-EBIT is -11.46. Based on the distribution chart, Hunan Nucien Pharmaceutical Co ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Hunan Nucien Pharmaceutical Co has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Nucien Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hunan Nucien Pharmaceutical Co ranks #999999 out of 682 companies for EV-to-EBIT. This places Hunan Nucien Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 16.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.08, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hunan Nucien Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Nucien Pharmaceutical Co's current EV-to-EBIT is -11.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Nucien Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co (SHSE:688189) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥3.22, compared to a current price of ¥6.67 — trading 107.1% above its estimated fair value. The current EV-to-EBIT is -11.46. Hunan Nucien Pharmaceutical Co's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hunan Nucien Pharmaceutical Co (SHSE:688189), the current EV-to-EBIT is -11.46 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hunan Nucien Pharmaceutical Co (SHSE:688189) Overvalued in 2026?
Based on GuruFocus' analysis, Hunan Nucien Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥6.67 is trading 107.1% above its estimated GF Value™ of ¥3.22.
GuruFocus considers Hunan Nucien Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:688189:
EV-to-EBIT: -11.46
GF Value™: ¥3.22 vs. price of ¥6.67 (107.1% above fair value)
No single metric tells the full story. See the SHSE:688189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hunan Nucien Pharmaceutical Co Ltd is a pharmaceutical company integrating drug research and development, production and sales. The company focuses on anti-infection, cardio-cerebral vascular, anti-tumor and other pharmaceutical fields. The company's business scope includes the manufacturing and sales of chemical pharmaceutical preparations, chemical pharmaceutical raw materials, biological drugs, chemical reagents, and auxiliaries.
48GF Score
Get the complete analysis for SHSE:688189
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688189 has been successfully added to your 
